Autopsy report · NCT03031470

Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation

“Taking into account that 5 out of 22 patients in the Reparixin group experienced EAD during the first stage of the study, according to the Protocol and the DMC conclusion, it was decided on the early termination of the study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 10 months after it had already started.
• Ran for about 2 years 1 month before it stopped.
• 40 participants enrolled.
• Results were posted on the registry 7 years 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Dompé Farmaceutici S.p.A

Sponsor type

Industry

Conditions

Ischemia-reperfusion Injury in Liver Transplant; Early Allograft Dysfunction

Interventions

Reparixin; Control

Participants

40

Sites

7

Countries

Belarus, Russia

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.